Last 1,174 INR
Change Today +54.85 / 4.90%
Volume 2.5M
As of 7:06 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

lupin ltd (LPC) Snapshot

Open
1,128
Previous Close
1,119
Day High
1,192
Day Low
1,113
52 Week High
07/30/14 - 1,192
52 Week Low
08/28/13 - 742.30
Market Cap
526.4B
Average Volume 10 Days
469.2K
EPS TTM
40.99
Shares Outstanding
448.6M
EX-Date
07/21/14
P/E TM
28.6x
Dividend
3.00
Dividend Yield
0.51%
Current Stock Chart for LUPIN LTD (LPC)

Related News

No related news articles were found.

lupin ltd (LPC) Related Businessweek News

No Related Businessweek News Found

lupin ltd (LPC) Details

Lupin Limited, a pharmaceutical company, produces, develops, and markets a range of branded and generic formulations and active pharmaceutical ingredients (APIs) primarily in India, the United States, and Japan. It offers various formulations for use in the areas of cephalosporin, cardiovascular (CVS), central nervous system (CNS), anti-asthma, anti-tuberculosis, diabetology, dermatology, gastro intestinal, and other therapy segments; and APIs for use in therapeutic areas of antibiotics, anti-tuberculosis, CVS, CNS, analgesics, and anti-gout. The company also develops and out-licenses its drug delivery technologies and platforms; and creates and develops biosimilars for various therapeutic indications, such as oncology, inflammation, antivirals, osteoporosis, and rheumatoid arthritis. In addition, it is engaged in the novel drug discovery and development programs for use in the treatment of metabolic disorders, pain and inflammation, autoimmune diseases, CNS disorders, cancer, and infectious diseases. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

12,984 Employees
Last Reported Date: 05/7/14
Founded in 1968

lupin ltd (LPC) Top Compensated Officers

Managing Director and Executive Director
Total Annual Compensation: 52.4M
Founder, Chairman, Member of Share Transfer C...
Total Annual Compensation: 31.8M
Executive Director, Member of Share Transfer ...
Total Annual Compensation: 3.6M
Compensation as of Fiscal Year 2014.

lupin ltd (LPC) Key Developments

Lupin Reportedly Planning To Bid For Drugs Auctioned By GlaxoSmith

Lupin Limited (BSE:500257) and private equity funds are reportedly planning to bid for a range of older drugs being auctioned by GlaxoSmithKline plc (LSE:GSK).

Lupin Limited, Board Meeting, Jul 15, 2014

Lupin Limited, Board Meeting, Jul 15, 2014. Agenda: To allot 19,574 fully paid up equity shares of INR 2 each.

Lupin Limited to Report Q1, 2015 Results on Jul 30, 2014

Lupin Limited announced that they will report Q1, 2015 results on Jul 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPC:IN 1,173.50 INR +54.85

LPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cipla Ltd/India 448.20 INR +7.25
Dr Reddy's Laboratories Ltd 2,823 INR +53.45
H Lundbeck A/S kr127.80 DKK +0.20
Ranbaxy Laboratories Ltd 586.05 INR -4.20
Salix Pharmaceuticals Ltd $131.48 USD +0.16
View Industry Companies
 

Industry Analysis

LPC

Industry Average

Valuation LPC Industry Range
Price/Earnings 27.4x
Price/Sales 4.4x
Price/Book 7.2x
Price/Cash Flow 23.9x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUPIN LTD, please visit www.lupinworld.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.